Luqa Pharmaceuticals Partners With Mayoly Spindler To Distribute Meteospasmyl

LUQA PHARMACEUTICALS PARTNERS WITH MAYOLY SPINDLER TO DISTRIBUTE METEOSPASMYL (ALVERINE CITRATE + SIMETICONE) IN HONG KONG AND MACAU JULY 6TH 2016 Hong Kong, PRC – Luqa Pharmaceuticals (“Luqa” or the “Company”), the China focused specialty pharmaceutical company, announces that it has entered into an exclusive long-term agreement for the distribution rights of METEOSPASMYL (ALVERINE CITRATE […]

Luqa Announces The Advancement of Its Medical Aesthetic Portfolio with Addition of Next Generation Facial Filler

Luqa Announces The Advancement of Its Medical Aesthetic Portfolio with Addition of Next Generation Facial Filler January 11th • Luqa announces the acquisition of long-term exclusive rights of a next generation facial filler for People’s Republic of China, Hong Kong and Macau • First launch is expected in the 2016 with a number of line-extensions […]

Luqa signs agreement with Laboratoires Genevrier for Innovative Vitiligo treatment product Viticell®

Luqa signs agreement with Laboratoires Genevrier for Innovative Vitiligo treatment product Viticell® Antibes, France/ Hong Kong, S.A.R. – December 7th, 2015 Luqa Pharmaceuticals (“Luqa”), the China focused specialty pharmaceutical company, today announces the signing of a licensing agreement with Laboratoires Genevrier for Viticell®, an innovative single-use kit for the treatment of Vitiligo to be commercialized […]

Luqa Pharmaceuticals To Participate At The Shanghai Forum

Shanghai (P.R.China) August 26, 2015 – Luqa Pharmaceuticals today announced its attendance to the conference “The Future of Healthcare and MedTech: A Keynote, Demo and Panel Discussion”, as part of the The Shanghai Forum series. The conference will be held in Shanghai on September 8, 2015 and Luqa’s CEO, Robert Braithwaite will participate as a […]